Secukinumab,Adalimumab
Novartis,Abbvie
['adalimumab', 'secukinumab']
surpass study
radiographic progression secukinumab versus adalimumab bs
presented by prof xenofon baraliakos
#eular2023
nz 
Annals of the Rheumatic Diseases (#1 research journal in Rheumatology) & RMD Open are the official @EULAR_ORG journals. High quality, peer reviewed research.